Desoximetasone Ointment USP, 0.25%, packaged in a) 100 grams tubes, NDC 52565-030-99; b) 60 grams tubes, NDC 52565-030-60; c) 15 grams tubes, NDC 52565-030-15, Rx Only, Teligent Pharma, Inc., Buena, New Jersey 08310.

Recall Insight

This FDA Drug action (record #D-0678-2022) was formally reported on March 30, 2022, with the manufacturer initiating the action on March 15, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Teligent Pharma, Inc. is listed as the recalling firm, operating out of Buena, NJ. Federal records indicate 13,989 tubes units are affected.

The documented reason for this recall is: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program. Distribution data in the federal record shows the product reached: Nationwide in the USA and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 4 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.